AMP.L

Amphion Innovations Plc
Amphion Innovations - Directorate Change
9th August 2019, 15:14
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6188I
Amphion Innovations PLC
09 August 2019
 

 

AMPHION INNOVATIONS PLC

 ("Amphion" or "the Company")

 

 

Directorate Change

 

London and New York, 9 August 2019 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that Philip Tansey and Stephen Austin have resigned as Non-executive Directors and will leave the Board with immediate effect. 

 

The Company has begun the process of seeking suitable candidates to fill these positions and will update shareholders accordingly.

 

Richard C.E. Morgan, Chief Executive Officer of Amphion said: "I would like to thank both Philip and Stephen for their service to Amphion.  We wish them both well for the future."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

 

For further information please contact:

 

Amphion Innovations

Tel: +1 (212) 210 6224

Charlie Morgan

 

 

 

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Tel: +44 (0)20 7886 2500

Emma Earl/ Freddy Crossley  (Corporate Finance)

 

Charles Leigh-Pemberton (Corporate Broking)

 

 

 

SP Angel Corporate Finance LLP (Joint Corporate Broker)

Tel: +44 (0) 20 3470 0470

David Hignell (Corporate Finance)

 

Vadim Alexandre (Corporate Broking)

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com

Anna Dunphy / Paul McManus

 

 

 
           

 

About Amphion Innovations plc

 

Amphion Innovations is a developer of medical, life science and technology businesses.

 

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

 

On the web: www.amphionplc.com 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAGMGGRKLKGLZM ]]>
TwitterFacebookLinkedIn